BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

406 related articles for article (PubMed ID: 27905203)

  • 21. Bortezomib, doxorubicin, and dexamethasone combination therapy followed by thalidomide and dexamethasone consolidation as a salvage treatment for relapsed or refractory multiple myeloma: analysis of efficacy and safety.
    Lee SS; Suh C; Kim BS; Chung J; Joo YD; Ryoo HM; Do YR; Jin JY; Kang HJ; Lee GW; Lee MH; Shim H; Kim K; Yoon SS; Bang SM; Kim HY; Lee JJ; Park J; Lee DS; Lee JH;
    Ann Hematol; 2010 Sep; 89(9):905-12. PubMed ID: 20349060
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Thalidomide and dexamethasone vs. bortezomib and dexamethasone for melphalan refractory myeloma: a randomized study.
    Hjorth M; Hjertner Ø; Knudsen LM; Gulbrandsen N; Holmberg E; Pedersen PT; Andersen NF; Andréasson B; Billström R; Carlson K; Carlsson MS; Flogegård M; Forsberg K; Gimsing P; Karlsson T; Linder O; Nahi H; Othzén A; Swedin A;
    Eur J Haematol; 2012 Jun; 88(6):485-96. PubMed ID: 22404182
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Phase I/II trial assessing bortezomib and melphalan combination therapy for the treatment of patients with relapsed or refractory multiple myeloma.
    Berenson JR; Yang HH; Sadler K; Jarutirasarn SG; Vescio RA; Mapes R; Purner M; Lee SP; Wilson J; Morrison B; Adams J; Schenkein D; Swift R
    J Clin Oncol; 2006 Feb; 24(6):937-44. PubMed ID: 16418495
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Lenalidomide plus dexamethasone is more effective than dexamethasone alone in patients with relapsed or refractory multiple myeloma regardless of prior thalidomide exposure.
    Wang M; Dimopoulos MA; Chen C; Cibeira MT; Attal M; Spencer A; Rajkumar SV; Yu Z; Olesnyckyj M; Zeldis JB; Knight RD; Weber DM
    Blood; 2008 Dec; 112(12):4445-51. PubMed ID: 18799726
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Autologous transplantation and maintenance therapy in multiple myeloma.
    Palumbo A; Cavallo F; Gay F; Di Raimondo F; Ben Yehuda D; Petrucci MT; Pezzatti S; Caravita T; Cerrato C; Ribakovsky E; Genuardi M; Cafro A; Marcatti M; Catalano L; Offidani M; Carella AM; Zamagni E; Patriarca F; Musto P; Evangelista A; Ciccone G; Omedé P; Crippa C; Corradini P; Nagler A; Boccadoro M; Cavo M
    N Engl J Med; 2014 Sep; 371(10):895-905. PubMed ID: 25184862
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Low-dose thalidomide in combination with oral weekly cyclophosphamide and pulsed dexamethasone is a well tolerated and effective regimen in patients with relapsed and refractory multiple myeloma.
    Kyriakou C; Thomson K; D'Sa S; Flory A; Hanslip J; Goldstone AH; Yong KL
    Br J Haematol; 2005 Jun; 129(6):763-70. PubMed ID: 15953002
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Bortezomib, melphalan, prednisone, and thalidomide for relapsed multiple myeloma.
    Palumbo A; Ambrosini MT; Benevolo G; Pregno P; Pescosta N; Callea V; Cangialosi C; Caravita T; Morabito F; Musto P; Bringhen S; Falco P; Avonto I; Cavallo F; Boccadoro M; ;
    Blood; 2007 Apr; 109(7):2767-72. PubMed ID: 17148584
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy of melphalan and prednisone plus thalidomide in patients older than 75 years with newly diagnosed multiple myeloma: IFM 01/01 trial.
    Hulin C; Facon T; Rodon P; Pegourie B; Benboubker L; Doyen C; Dib M; Guillerm G; Salles B; Eschard JP; Lenain P; Casassus P; Azaïs I; Decaux O; Garderet L; Mathiot C; Fontan J; Lafon I; Virion JM; Moreau P
    J Clin Oncol; 2009 Aug; 27(22):3664-70. PubMed ID: 19451428
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Thalidomide, dexamethasone and lovastatin with autologous stem cell transplantation as a salvage immunomodulatory therapy in patients with relapsed and refractory multiple myeloma.
    Hus M; Grzasko N; Szostek M; Pluta A; Helbig G; Woszczyk D; Adamczyk-Cioch M; Jawniak D; Legiec W; Morawska M; Kozinska J; Waciński P; Dmoszynska A
    Ann Hematol; 2011 Oct; 90(10):1161-6. PubMed ID: 21698395
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Thalidomide and dexamethasone combination for refractory multiple myeloma.
    Dimopoulos MA; Zervas K; Kouvatseas G; Galani E; Grigoraki V; Kiamouris C; Vervessou E; Samantas E; Papadimitriou C; Economou O; Gika D; Panayiotidis P; Christakis I; Anagnostopoulos N
    Ann Oncol; 2001 Jul; 12(7):991-5. PubMed ID: 11521808
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thalidomide-dexamethasone plus pegylated liposomal doxorubicin vs. thalidomide-dexamethasone: a case-matched study in advanced multiple myeloma.
    Offidani M; Bringhen S; Corvatta L; Falco P; Marconi M; Avonto I; Piersantelli MN; Polloni C; Boccadoro M; Leoni P; Palumbo A
    Eur J Haematol; 2007 Apr; 78(4):297-302. PubMed ID: 17286608
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Pomalidomide (CC4047) plus low-dose dexamethasone as therapy for relapsed multiple myeloma.
    Lacy MQ; Hayman SR; Gertz MA; Dispenzieri A; Buadi F; Kumar S; Greipp PR; Lust JA; Russell SJ; Dingli D; Kyle RA; Fonseca R; Bergsagel PL; Roy V; Mikhael JR; Stewart AK; Laumann K; Allred JB; Mandrekar SJ; Rajkumar SV
    J Clin Oncol; 2009 Oct; 27(30):5008-14. PubMed ID: 19720894
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Elotuzumab in combination with thalidomide and low-dose dexamethasone: a phase 2 single-arm safety study in patients with relapsed/refractory multiple myeloma.
    Mateos MV; Granell M; Oriol A; Martinez-Lopez J; Blade J; Hernandez MT; Martín J; Gironella M; Lynch M; Bleickardt E; Paliwal P; Singhal A; San-Miguel J
    Br J Haematol; 2016 Nov; 175(3):448-456. PubMed ID: 27434748
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclophosphamide, thalidomide, and dexamethasone (CTD) as initial therapy for patients with multiple myeloma unsuitable for autologous transplantation.
    Morgan GJ; Davies FE; Gregory WM; Russell NH; Bell SE; Szubert AJ; Navarro Coy N; Cook G; Feyler S; Byrne JL; Roddie H; Rudin C; Drayson MT; Owen RG; Ross FM; Jackson GH; Child JA;
    Blood; 2011 Aug; 118(5):1231-8. PubMed ID: 21652683
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Phase 2 study of clarithromycin, pomalidomide, and dexamethasone in relapsed or refractory multiple myeloma.
    Mark TM; Forsberg PA; Rossi AC; Pearse RN; Pekle KA; Perry A; Boyer A; Tegnestam L; Jayabalan D; Coleman M; Niesvizky R
    Blood Adv; 2019 Feb; 3(4):603-611. PubMed ID: 30792190
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A phase II trial of continuous ixazomib, thalidomide and dexamethasone for relapsed and/or refractory multiple myeloma: the Australasian Myeloma Research Consortium (AMaRC) 16-02 trial.
    Bergin K; Yuen F; Wallington-Beddoe C; Kalff A; Sirdesai S; Reynolds J; Spencer A
    Br J Haematol; 2021 Aug; 194(3):580-586. PubMed ID: 33991421
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Isatuximab plus pomalidomide and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed and refractory multiple myeloma (ICARIA-MM): a randomised, multicentre, open-label, phase 3 study.
    Attal M; Richardson PG; Rajkumar SV; San-Miguel J; Beksac M; Spicka I; Leleu X; Schjesvold F; Moreau P; Dimopoulos MA; Huang JS; Minarik J; Cavo M; Prince HM; Macé S; Corzo KP; Campana F; Le-Guennec S; Dubin F; Anderson KC;
    Lancet; 2019 Dec; 394(10214):2096-2107. PubMed ID: 31735560
    [TBL] [Abstract][Full Text] [Related]  

  • 38. The efficacy and safety of the low-thalidomide dose CTD (cyclophosphamide, thalidomide, dexamethasone) regimen in patients with multiple myeloma--a report by the Polish Myeloma Study Group.
    Dmoszynska A; Walter-Croneck A; Hus I; Grzasko N; Manko J; Jedrzejczak WW; Charlinski G; Usnarska-Zubkiewicz L; Skotnicki A; Wolska-Smolen T; Piszcz J; Kloczko J
    Leuk Res; 2010 Oct; 34(10):1330-5. PubMed ID: 20627385
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Consolidation therapy with low-dose thalidomide and prednisolone prolongs the survival of multiple myeloma patients undergoing a single autologous stem-cell transplantation procedure.
    Spencer A; Prince HM; Roberts AW; Prosser IW; Bradstock KF; Coyle L; Gill DS; Horvath N; Reynolds J; Kennedy N
    J Clin Oncol; 2009 Apr; 27(11):1788-93. PubMed ID: 19273705
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Current treatment strategies with lenalidomide in multiple myeloma and future perspectives.
    Larocca A; Cavallo F; Mina R; Boccadoro M; Palumbo A
    Future Oncol; 2012 Oct; 8(10):1223-38. PubMed ID: 23130924
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.